Wall Street Zen Lowers iRadimed Rating; Insider Activity Revealed

Equities researchers at Wall Street Zen have downgraded iRadimed Corp. (NASDAQ: IRMD) from a “strong-buy” rating to a “buy” rating, according to a research note issued on October 8, 2023. This change reflects a cautious sentiment among analysts regarding the company’s stock performance. In contrast, Weiss Ratings reaffirmed a “buy (B-)” rating for iRadimed, indicating some level of confidence in the company’s future.

Currently, two investment analysts have assigned a Buy rating to iRadimed. MarketBeat data shows that the company holds an average rating of “Buy” along with a consensus target price of $72.00.

Insider Trading Activity

Recent insider transactions have also drawn attention. On August 6, 2023, Director Monty K. Allen sold 1,102 shares of iRadimed stock at an average price of $69.10, amounting to a total value of $76,148.20. Following this transaction, Allen retained ownership of 19,898 shares, valued at approximately $1,374,951.80, reflecting a decrease of 5.25% in his ownership stake.

In a separate transaction, CEO Roger E. Susi sold 5,000 shares on October 21, 2023, at an average price of $74.82, resulting in a total transaction value of $374,100.00. After this sale, Susi owned 2,332,500 shares, worth around $174,517,650, representing a slight decrease of 0.21% in his position. The details of these transactions were disclosed in filings with the Securities and Exchange Commission.

In the last quarter, insiders collectively sold a total of 31,102 shares of iRadimed stock, valued at $2,235,398. Notably, company insiders currently own 36.80% of the total stock.

Institutional Investment Trends

Recent activity among institutional investors has also been noteworthy. Roubaix Capital LLC acquired a new stake in iRadimed valued at approximately $2,526,000 during the first quarter. SG Americas Securities LLC significantly increased its stake in the second quarter by 408.8%, now owning 36,516 shares worth about $2,183,000 after purchasing an additional 29,339 shares.

Other investors include Nuveen LLC and Johnson Investment Counsel Inc., both of which initiated new positions in iRadimed during the first half of the year, valued at approximately $1,418,000 and $1,534,000, respectively. Vanguard Group Inc. has also increased its stake by 3.3%, now holding 554,451 shares, valued at $29,098,000. Collectively, institutional investors and hedge funds control 92.34% of iRadimed’s stock.

iRadimed Corp., founded in July 1992 and headquartered in Winter Springs, FL, specializes in the development and marketing of Magnetic Resonance Imaging (MRI) compatible medical devices. The company is particularly noted for its non-magnetic intravenous infusion pump system, designed specifically for MRI procedures.

As market dynamics continue to evolve, stakeholders will be keen to monitor iRadimed’s performance in light of these recent ratings and insider activities.